Acambis reports earnings, lowers guidance

Acambis (LSE:ACM; ACAM) reported second quarter revenues of L32.5 million ($58.4 million), down 20% from L40.5 million ($72.8 million) for the same period last year. ACM said the decrease reflects lower sales of smallpox vaccine under its contract with the CDC. ACM also said the CDC does not intend to buy the 26.5 million doses of smallpox vaccine remaining under a 54 million dose contract. The company added that it expects to defer L15 million in revenue to 2005.

ACM's second quarter basic EPS was 18.1p, which includes a L10.2 million payment related to a legal settlement. ...